Eric Easom, CEO of AN2 Therapeutics

January 7, 2022 10:57 AM ESTUpdated 11:17 AM

Anacor veterans raise $80M in bid to tackle rare lung disease with boron-based inhibitors

Paul Schloesser

Associate Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Large pharma companies spell out reasons why tariffs will harm US investments

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

DNA giant Illumina spawned an ecosystem of competitors and customers

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation